The Food and Drug Administration (opens in new tab) on Monday approved giredestrant (Wilserdly, Genentech (opens in new tab)), an oral estrogen-receptor antagonist, in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred or progressed after endocrine therapy. The agency said the recommended giredestrant dose is 30 milligrams once daily. Reuters (opens in new tab) also reported the approval and the 30-milligram dose, and said the FDA authorized a blood test to identify eligible patients.

The evidence came from the Phase III evERA trial. In the ESR1-mutated population, median progression-free survival was 10 months with giredestrant plus everolimus, versus 5.5 months with physician's-choice endocrine therapy plus everolimus, the FDA said, a hazard ratio of 0.38. Objective response rates were 27% and 14%, respectively, and overall survival data were still immature. Reuters (opens in new tab) described the same progression-free-survival result as a 62% reduction in the risk of disease progression or death, a figure also used in Genentech (opens in new tab)'s release.

Genentech (opens in new tab) said the FDA is also reviewing giredestrant in the adjuvant, or early-stage, setting, with a decision expected by Nov. 30, a company claim about a separate application. Monday's approval is limited to the previously treated, ESR1-mutated advanced or metastatic population described by the FDA.